Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
743 INCLINE-101: preliminary safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in patients with advanced or metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
